Controlled document PF-016A
PLEXUS LUMBOSACRALIS Phase 2 Master Formula
Record identification
- Document ID
- PF-016A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-016A
PRODUCT FORMULA CARD
SIRIAM PLEXUS LUMBOSACRALIS DUO – PHASE 2 (NERVE INTEGRATION)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PLS-002 |
| MF-016 |
| PF-016A |
| PLEXUS LUMBOSACRALIS DUO – Phase 2 |
| L4–S2 |
| Nerve Integration |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurodermal stabilisation of the lumbosacral plexus |
| L4–S2 |
| Myofascial recovery, sciatic chain integration and autonomic harmonisation |
| Phase 2 – Integration |
| Topical Magistral Cream |
2. MASTER FORMULA
The ingredient quantities follow the uploaded Phase 2 magistral fiche with the agreed SQMS naming conventions.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| 67.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| 16.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| 2.00 |
| g |
| W |
| SC-002 |
| MSM |
| 2.50 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| 1.50 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| 0.33 |
| g |
| D |
| BE-010 |
| Hypericum perforatum D6 |
| 0.30 |
| mL |
| C |
| BE-004 |
| Bacopa monnieri |
| 0.70 |
| mL |
| C |
| BE-005 |
| Nymphaea caerulea (Blue Lotus) |
| 1 drop / 300 g |
| drop |
| C |
| BE-011 |
| Frankincense CO₂ |
| 2 drops |
| drop |
| C |
| AC-004 |
| Coenzyme Q10 |
| 0.33 |
| g |
| D |
| BE-002 |
| Copaiba Oil |
| 0.60 |
| mL |
| C |
| AC-008 |
| Magnesium Bisglycinate |
| 0.50 |
| g |
| W |
| OC-003 |
| Squalane |
| 2.00 |
| g |
| L |
| AC-002 |
| Betaine (TMG) |
| 0.70 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| 1.20 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| 0.70 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| 2.00 |
| g |
| C |
| EO-001 |
| Black Spruce Essential Oil (optional) |
| 1 drop |
| drop |
| C |
| PR-001 |
| Cosgard 221 |
| 0.70 |
| g |
| C |
3. MANUFACTURING WORKFLOW
Standard SQMS Lanette Manufacturing Workflow (SOP-001), with Bacopa, Blue Lotus, homeopathic components and Frankincense CO₂ incorporated during the cooling phase.
4. QUALITY CONTROL
Standard SQMS Quality Control checklist.
5. BATCH RELEASE
Standard SQMS Batch Release form.
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Posterior Zone
Additional Posterior Zones
Frequency
Weeks 1–2
Week 3
Week 4
Week 5
Relapse
The treatment schedule and application zones follow the magistral protocol.
| Value |
|---|
| L4–S2 |
| Trochanteric region |
| Lateral hip |
| Tensor fasciae latae projection |
| L4–S2 paravertebral |
| Gluteal region, piriformis, SI region, proximal ITB |
| 1–2× daily |
| PLEXUS LUMBOSACRALIS-1 |
| Morning PLEXUS LUMBOSACRALIS-2 / Evening PLEXUS LUMBOSACRALIS-1 |
| PLEXUS LUMBOSACRALIS-2 |
| PLEXUS LUMBOSACRALIS-2 (evening) |
| 3 days PLEXUS LUMBOSACRALIS-1 |
Related documents
Platform modules